افزایش فشار خون ریوی: جنبه های مولکولی مداخله درمانی / Pulmonary Hypertension: Molecular Aspects of Current Therapeutic Intervention and Future Direction

افزایش فشار خون ریوی: جنبه های مولکولی مداخله درمانی Pulmonary Hypertension: Molecular Aspects of Current Therapeutic Intervention and Future Direction

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • ناشر : Wiley
  • چاپ و سال / کشور: 2018

توضیحات

رشته های مرتبط پزشکی
گرایش های مرتبط انکولوژی، پزشکی ریه
مجله فیزیولوژی سلولی – Journal of Cellular Physiology
دانشگاه Indo Soviet College of Pharmacy – Moga – Punjab

منتشر شده در نشریه وایلی
کلمات کلیدی انگلیسی Pulmonary Hypertension, Pathophysiology, Molecular Signaling, Vascular endothelial dysfunction, Potential target sites

Description

Introduction Pulmonary hypertension (PH) is a diverse group of fatal disorders characterized by a sustained increase in pulmonary artery pressure and vascular resistance due to pulmonary artery hyper-constriction (Cogolludo et al., 2007). The elevated blood pressure in the pulmonary artery leads to cardio-muscular stress followed by gradual enlargement of the right ventricle. Similarly, the reduced production of vasodilator including prostacyclin (PGI2) and nitric oxide (NO) or consequent increase in endogenous vasoconstrictors like endothelin-1 (ET-1) and thromboxane A2 in pulmonary circulation leads to pulmonary endothelial dysfunction (Cogolludo et al., 2007). The availability of endothelial derived relaxation factor (EDRF) ‘NO’ was noted to be reduced in the pulmonary circulation due to impaired activation of endothelial nitric oxide synthase (eNOS) (Chester and Yacoub, 2014). Moreover, increased level of serotonin endorses the pulmonary artery smooth muscle cell (PASMC) proliferation, vasoconstriction and local microthrombosis (Lang and Madani, 2014). Patients with PH have high levels of serotonin in circulation that indicate the influence of serotonin on induction of PH (MacLean et al., 2000). Indeed, several potential sites including prostanoids, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble gunanyl cyclase stimulators, Rho kinase inhibitors, serotonin receptor antagonist and serotonin transporter blockers, statins, peroxisome proliferator activated receptor agonist, calcium channel blockers, potassium channel openers, tyrosine kinase inhibitors are currently target to impede the vulnerability of PH. Preclinical evidence implicate the role of Rho-kinase in the pathogenesis of pulmonary hypertension (JasińskaStroschein et al., 2014). Rho kinase suppresses the myosin phosphatase and augments the contractility of pulmonary artery smooth muscle cells (PASMC) in rats. Transient receptor potential channels (TRPC) has also found to be over expressed in pulmonary hypertension and influence the smooth muscle cell (PASMC) proliferation and pulmonary vascular medial hypertrophy (Malczyk et al., 2017). Certainly, increased oxidative stress contributes to pulmonary vascular cell growth and right ventricular hypertrophy (Sharma et al., 2015). Evidence suggests that reactive oxygen species (ROS) exceeds the quenching capacity of antioxidant mechanisms of the cell and protein carbonylation may be involved in the pathology of PH (Wong et al., 2013; Sharma et al., 2015).
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری